- Fee assured
- Verified this account
Professor Gordon Rustin qualified from the Middlesex Hospital, London in 1971. He was appointed Senior Lecturer in Medical Oncology at the Charing Cross Hospital in 1984, but moved full-time to Mount Vernon Hospital to become Director of Medical Oncology in 1995.
He was awarded an Honorary Professorship by UCL in 2001 and in 2011 created Professor of Cancer Therapy at the Institute of Cancer Research. He has published over 300 papers on management of gynaecological cancers and germ cell tumors, the use of tumor markers, especially CA 125, and on phase I, II and III trials. His definitions using CA 125 to define response and progression of ovarian carcinoma are internationally known as the “Rustin criteria”.
He gave the number 1 plenary lecture at the 2009 annual meeting of the American Society of Clinical oncology, presenting the results of the MRC OVO5 / EORTC 55955 trial which has since been published in the Lancet. This trial showed that patients benefit from delaying chemotherapy. Gordon Rustin through the use of use all his communication skills is slowly persuading the international community to accept these counterintuitive results and change practice.
As chief investigator of the phase I trials of DMXAA, CA4P and OXI4503 he has developed a unique experience of running trials of vascular disruptive agents (VDAs). He has led the world in introducing functional imaging into determining the activity of VDAs. For 5 years until 2008 he was chairman of the ovarian cancer sub group of the NCRI gynecological clinical studies group.
Areas of interest
New Drug Development
Current NHS consultant posts held
Professor of Medical Oncology at Mount Vernon Cancer Centre, Northwood, Middlesex
Clinical trials of new agents, anti-vascular therapies, improving the use of tumour markers, especially CA125
Golf, sailing, gardening, music, theatre
Professorships at Institute of Cancer Research, University College London , and University of Hertfordshire,
Over 350 publications
Reference number 1492156
- BMI Bishops Wood Hospital, HA6 2JW
- 08:30 - 13:30
- 01923 834211
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
In the event of an urgent query following treatment, Bupa members should use the following contact details
Pinner Ward 01923834221
Information for healthcare professionals (Bupa patients only, last 12 months)
Clinical supervision and planning for delivery of chemotherapy cycle 1 - 21 days - (5-50)
Clinical supervision and planning for delivery of chemotherapy cycle 1 - 28 days - (5-50)
BMI Bishops Wood Hospital (5-50)
Clinical supervision and planning for delivery of chemotherapy cycle 1 - 14 days - (5-50)